Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Deferred Taxes (2019 - 2025)

Historic Deferred Taxes for Vanda Pharmaceuticals (VNDA) over the last 8 years, with Q3 2025 value amounting to -$6.0 million.

  • Vanda Pharmaceuticals' Deferred Taxes fell 9345.85% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.7 million, marking a year-over-year decrease of 9629.11%. This contributed to the annual value of -$6.5 million for FY2024, which is 40404.35% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Deferred Taxes stood at -$6.0 million for Q3 2025, which was down 9345.85% from -$8.0 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Deferred Taxes peaked at $4.4 million during Q1 2022, and registered a low of -$8.0 million during Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Deferred Taxes value was -$246000.0 (recorded in 2024), while the average stood at -$1.1 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Deferred Taxes skyrocketed by 28077.59% in 2022, and later plummeted by 306951.22% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Deferred Taxes (Quarter) stood at $1.3 million in 2021, then crashed by 68.24% to $417000.0 in 2022, then plummeted by 1894.72% to -$7.5 million in 2023, then skyrocketed by 74.43% to -$1.9 million in 2024, then crashed by 212.12% to -$6.0 million in 2025.
  • Its Deferred Taxes stands at -$6.0 million for Q3 2025, versus -$8.0 million for Q2 2025 and -$7.8 million for Q1 2025.